News Releases

The information set forth in each press release posted on this page was factually accurate on the date it was issued. While these press releases remain on the Company's website, the Company assumes no duty to update the information to reflect subsequent developments. Consequently, readers of the press releases should not rely upon the information as current or accurate after their issuance dates.

Date Title
07/24/24
Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery
07/16/24
Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call
07/08/24
Charles River to Perform Plasmid Manufacturing for AAVantgarde
06/25/24
Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus
06/17/24
Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy
06/11/24
Charles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives
06/06/24
Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville
06/04/24
Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research
06/03/24
Charles River Laboratories to Present at William Blair and Jefferies Conferences
05/30/24
Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
05/09/24
Charles River Laboratories Announces First-Quarter 2024 Results
05/02/24
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
04/22/24
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
04/16/24
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
04/12/24
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
04/11/24
Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
04/09/24
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
04/04/24
Charles River to Perform Plasmid Production for Ship of Theseus
04/01/24
Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
03/27/24
Charles River Laboratories Publishes 2023 Corporate Citizenship Report
03/21/24
Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
03/14/24
Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
03/12/24
Charles River Laboratories to Present at Barclays Global Healthcare Conference
02/21/24
Charles River and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing
02/20/24
Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells
02/14/24
Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance
01/29/24
Charles River Introduces the First Rapid Animal-Free Bacterial Endotoxin Test
01/24/24
Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors
01/23/24
Charles River Laboratories Schedules Fourth-Quarter 2023 Earnings and 2024 Guidance Release and Conference Call
01/16/24
Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing
01/08/24
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

Featured Report

Charles River Corporate Citizenship Report
View PDF
Print PDF